Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

Story continues below

On June 15, 2018, Blueprint Medicines Corporation (the “Company”) issued a press release announcing new data from its ongoing Phase 1 clinical trial evaluating avapritinib for the treatment of advanced systemic mastocytosis. The data will be presented on Friday, June 15, 2018 in a poster presentation at the 23rd Congress of the European Hematology Association in Stockholm, Sweden. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the poster presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.


Blueprint Medicines Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 bpmc_Ex99_1 Exhibit 99.1   Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity   – Overall Response Rate of 83%  – – Durable Ongoing Responses Up to 22 Months – –  All Patients Evaluable on Measures of Mast Cell Burden Showed Marked Improvements,…
To view the full exhibit click here

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

An ad to help with our costs